Patents by Inventor Wolfgang J. Rettig
Wolfgang J. Rettig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6613879Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.Type: GrantFiled: April 21, 2000Date of Patent: September 2, 2003Assignees: Boehringer Ingelheim Pharma KG, Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Raymond A. Firestone, Wolfgang J. Rettig, Martin Lenter, Stefan Peters, Pilar Garin-Chesa, Juergen Mack, Dietmar Leipert, John E. Park, Leila A. Telan
-
Publication number: 20030143229Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: ApplicationFiled: June 3, 2002Publication date: July 31, 2003Applicant: Boehringer Ingelheim International GmbHInventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Leger, Jose William Saldanha
-
Patent number: 6455677Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: GrantFiled: April 29, 1999Date of Patent: September 24, 2002Assignee: Boehringer Ingelheim International GmbHInventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Lèger, Jose William Saldanha
-
Patent number: 6391302Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: August 7, 2000Date of Patent: May 21, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Publication number: 20020052480Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: ApplicationFiled: April 29, 1999Publication date: May 2, 2002Inventors: JOHN EDWARD PARK, PILAR GARIN-CHESA, UWE BAMBERGER, WOLFGANG J. RETTIG, OLIVIER LEGER, JOSE WILLIAM SALDANHA
-
Patent number: 6348195Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumor cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: June 26, 2000Date of Patent: February 19, 2002Assignee: Memorial Sloan Kettering Cancer CenterInventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 6217868Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: November 2, 1998Date of Patent: April 17, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 6124106Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: March 10, 1999Date of Patent: September 26, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 6090930Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: January 27, 1998Date of Patent: July 18, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5952484Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: December 5, 1996Date of Patent: September 14, 1999Assignee: Sloan-Kettering Cancer CenterInventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5843448Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.Type: GrantFiled: November 17, 1995Date of Patent: December 1, 1998Assignee: Ludwig Institute of Cancer ResearchInventors: Yao-Tseng Chen, Elisabeth Stockert, Yachi Chen, Pilar Garin-Chesa, Wolfgang J. Rettig, Lloyd J. Old
-
Patent number: 5811522Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: May 20, 1996Date of Patent: September 22, 1998Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5646253Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: March 8, 1994Date of Patent: July 8, 1997Assignees: Memorial Sloan-Kettering Cancer Center, Scotgen Biopharmaceuticals, Inc.Inventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5618534Abstract: An antigen which is specific to vascular endothelium is described. Described is a cell surface antigen which consists of four subunits; of 190, 145, 125 and 110 kd as determined by SDS-PAGE under reducing conditions as is a monoclonal antibody specific to this antigen. Uses, both diagnostic and therapeutic, are also described.Type: GrantFiled: September 28, 1995Date of Patent: April 8, 1997Assignee: Memorial Sloan Kettering Cancer CenterInventors: Maria P. Sanz-Moncasi, Pilar Garin-Chesa, Elisabeth Stockert, Lloyd J. Old, Wolfgang J. Rettig
-
Patent number: 5587299Abstract: The invention describes the identification and isolation of nucleic acid molecules which code for fibroblast activation protein alpha, or "FAP.alpha.". Various applications of the isolated molecules are also described.Type: GrantFiled: April 20, 1994Date of Patent: December 24, 1996Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Wolfgang J. Rettig, Matthew J. Scanlan, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5541104Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.Type: GrantFiled: February 1, 1994Date of Patent: July 30, 1996Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.Inventors: Yao-Tseng Chen, Elisabeth Stockert, Yachi Chen, Pilar Garin-Chesa, Wolfgang J. Rettig, Pierre van der Bruggen, Thierry Boon-Falleur, Lloyd J. Old
-
Patent number: 5536641Abstract: An antigen which is specific to vascular endothelium is described. Described is a cell surface antigen which consists of four subunits, of 190, 145, 125 and 110 kd as determined by SDS-PAGE under reducing conditions as is a monoclonal antibody specific to this antigen. Uses, both diagnostic and therapeutic, are also described.Type: GrantFiled: May 17, 1994Date of Patent: July 16, 1996Assignee: Memorial Sloane Kittering Cancer CenterInventors: Maria P. Sanz-Moncasi, Pilar Garin-Chesa, Elisabeth Stockert, Lloyd J. Old, Wolfgang J. Rettig
-
Patent number: 5437865Abstract: The invention is an isolated, sialylated glycoprotein, referred to as endosialin, which is expressed by tumor associated vascular endothelium and not normal vascular endothelium. The protein portion of the glycoprotein has a molecular weight of about 95 kilodaltons as determined by SDS-PAGE, and the glycoprotein has a molecular weight of about 165 kilodaltons, also as determined by SDS-PAGE. The oligosaccharides are linked by O-linkages to the protein. The glycoprotein is useful for making antibodies which are in turn used to identify tumor associated vascular endothelium.Type: GrantFiled: March 30, 1994Date of Patent: August 1, 1995Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Pilar Garin-Chesa, Wolfgang J. Rettig, Lloyd J. Old
-
Patent number: 5342757Abstract: The invention involves monoclonal antibodies which specifically bind to a cell surface antigen characteristic of tumor vascular endothelium. The antigen, referred to as endosialin, is a glycoprotein and has a molecular weight of about 165 kDa as determined by SDS-PAGE. The protein portion of the molecule has a molecular weight of about 95 kDa. Also disclosed are various uses of the monoclonal antibody and the antigen.Type: GrantFiled: November 13, 1992Date of Patent: August 30, 1994Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer CenterInventors: Pilar Garin-Chesa, Wolfgang J. Rettig, Lloyd J. Old
-
Patent number: 5059523Abstract: This invention provides a method of identifying mesenchymal tissues as normal, proliferatively active or malignant. This invention also provides a method of distinguishing subsets of sarcomas with distinctive antigenic phenotypes. This invention also provides a method of diagnosing mesenchymal tumors. Finally, this invention provides a monoclonal antibody designated G171 and the hybridoma cell line producing said monoclonal antibody (ATCC No. HB9254).Type: GrantFiled: May 2, 1988Date of Patent: October 22, 1991Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Wolfgang J. Rettig, Pilar Garin-Chesa, H. Richard Beresford, Herbert F. Oettgen, Myron R. Melamed, Lloyd J. Old